This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Merck Animal Health Acquires TARGAN
Business acquisition

Merck Animal Health Acquires TARGAN

Analysis based on 6 articles · First reported Jun 11, 2026 · Last updated Jun 12, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition of Tarkhan by Ceva Santé Animale is expected to positively impact the animal health market by introducing advanced biodevice technology for poultry, potentially increasing efficiency and animal welfare in commercial hatcheries. This move strengthens Merck & Co.'s position in the biopharmaceutical and animal agriculture technology sectors.

Animal Health Biotechnology Agriculture
Event Summary

Ceva Santé Animale, a division of Merck & Co., has signed a definitive agreement to acquire Tarkhan, a privately held innovator in biodevice solutions for the poultry industry. Ceva Santé Animale has been a significant investor in Tarkhan since 2017. The acquisition, expected to close in the third quarter of 2026, will broaden Ceva Santé Animale's portfolio with Tarkhan's WingScan technology for gender identification and high-speed precision ocular spray technology for vaccine administration in chicks. This strategic move aims to enhance poultry performance and strengthen Ceva Santé Animale's biopharmaceutical presence globally.

Entities Involved
oth
Tarkhan
Tarkhan is being acquired by Ceva Santé Animale, gaining access to resources and infrastructure to deploy its innovative biodevice technology. This acquisition validates its technology and business model.
Importance 90.0 Sentiment 70.0
per
Rick DeLuca
Rick DeLuca, President of Ceva Santé Animale, commented on the strategic benefits of the acquisition, highlighting its role in expanding the company's portfolio and technological capabilities.
Importance 40.0 Sentiment 30.0
per
Ramin Karimpour
Ramin Karimpour, Founder and CEO of Tarkhan, expressed gratitude for Ceva Santé Animale's partnership and the opportunities the acquisition will bring for deploying Tarkhan's technology.
Importance 40.0 Sentiment 30.0
priv
Mountain Group Partners
Mountain Group Partners is an investor in Tarkhan.
Importance 10.0 Sentiment 10.0
priv
NovaQuest Capital Management
NovaQuest Capital Management is an investor in Tarkhan.
Importance 10.0 Sentiment 10.0
priv
Alta Park Capital
Alta Park Capital is an investor in Tarkhan.
Importance 10.0 Sentiment 10.0
oth
Symbiotic Capital
Symbiotic Capital is an investor in Tarkhan.
Importance 10.0 Sentiment 10.0
stock
Meritz Securities
Importance 0.0 Sentiment 0.0
priv
Live Oak Bank
Importance 0 Sentiment 0
priv
Ceva Santé Animale
Importance 0 Sentiment 0
priv
Davis Polk
Importance 0 Sentiment 0
stock
Merck & Co.
Importance 0 Sentiment 0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.